Journal of Allergy and Clinical Immunology最新文献

{"title":"Evolution of mast cell research associated with the Laboratory of Allergic Diseases, 1985-2022: Summary of the 2023 NIAID Symposium","authors":"Hirsh D. Komarow MD ,&nbsp;Gunnar Nilsson PhD ,&nbsp;Yoshimichi Okayama MD, PhD ,&nbsp;Yoseph Mekori MD ,&nbsp;Ana Olivera PhD ,&nbsp;Peter Valent MD ,&nbsp;Karin Hartmann MD ,&nbsp;Knut Brockow MD ,&nbsp;Glenn Cruse PhD ,&nbsp;Jonathan Lyons MD ,&nbsp;Amy D. Klion MD ,&nbsp;Cem Akin MD, PhD ,&nbsp;Jason R. Gotlib MD, MS ,&nbsp;Mariana Castells MD, PhD ,&nbsp;Stephen J. Galli MD ,&nbsp;Dean D. Metcalfe MD, MS ,&nbsp;Melody C. Carter MD","doi":"10.1016/j.jaci.2025.06.029","DOIUrl":"10.1016/j.jaci.2025.06.029","url":null,"abstract":"<div><div>Present and former investigators of the Mast Cell Biology Section (MCBS) of the Laboratory of Allergic Diseases (LAD) and their colleagues organized a daylong symposium in October 2023 to honor the outstanding contributions of the MCBS headed by Dr Dean D. Metcalfe, who recently retired from his leadership role in this department. The symposium featured an overview of discoveries that advanced the scientific understanding of the human mast cell (MC) lineage and compartment over the preceding 3 decades. Insights into mechanisms and molecules contributing to MC expansion and function in health and disease, MC activation, and neoplastic MCs in mastocytosis were presented. The impact of these discoveries on the diagnosis and management of allergic diseases and MC disorders, as well as unmet needs in MC research, were reviewed. A summary of these discussions is provided.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 579-589"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144594431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus summary on the definition of asthma remission","authors":"Rohit K. Katial MD ,&nbsp;Michael E. Wechsler MD, MMSc ,&nbsp;Praveen Akuthota MD ,&nbsp;David J. Jackson FRCP, MSc, PhD ,&nbsp;Ian Pavord MA, DM, FRCP, FERS, FMedSci ,&nbsp;Linda Rogers MD ,&nbsp;Daniel J. Jackson MD ,&nbsp;Josef Smolen MD ,&nbsp;Flavia Cecilia Lega Hoyte MD","doi":"10.1016/j.jaci.2025.05.033","DOIUrl":"10.1016/j.jaci.2025.05.033","url":null,"abstract":"<div><div>Striving for clinical remission in asthma is a new approach to treatment whose time has come. It is critical that a widely accepted definition of asthma clinical remission be developed that is agreed to be both practical and meaningful to clinicians, researchers, and patients. To advance this development process, National Jewish Health convened a panel of experts in the field for a 2-day virtual workshop to critically assess previously proposed definitions of remission in asthma and other immune-mediated diseases and the latest evidence from clinical studies of remission in patients with asthma treated with biologic therapies. After careful deliberation, we present the panel’s definition of asthma clinical remission and identify unresolved issues that deserve further investigation and wider discussion among different stakeholder groups.</div><div><em>This article is part of a supplement supported by an educational grant from AstraZeneca Pharmaceuticals. The content of this article was developed independently by National Jewish Health and the article authors</em>.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages S20-S24"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145183683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antigen-specific immune responses and microbiota interactions in skin: Insights into autoimmune skin diseases and emerging therapeutic strategies","authors":"Hayato Takahashi MD, PhD ,&nbsp;Keitaro Fukuda MD, PhD ,&nbsp;Yoshihiro Ito MD, PhD ,&nbsp;Masayuki Amagai MD, PhD","doi":"10.1016/j.jaci.2025.05.021","DOIUrl":"10.1016/j.jaci.2025.05.021","url":null,"abstract":"<div><div>The skin plays a vital role in serving as a physical and immunologic barrier against external insults while orchestrating complex immune responses. Autoimmune skin diseases including pemphigus, vitiligo, and alopecia areata illustrate the intricate interplay between antigen-specific immunity and tissue-specific pathologies. Pemphigus serves as a model to understand the dynamics of peripheral immune tolerance and the interplay between humoral and cellular autoimmunity, emphasizing the role of regulatory T cells in controlling autoreactive responses. Similarly, vitiligo and alopecia areata highlight the pathological contribution of resident memory CD8⁺ T cells and IFN-γ signaling, identifying potential therapeutic targets such as the IL-15 signaling pathway to address disease intractability. In addition to autoimmune mechanisms, the skin microbiota profoundly influences local and systemic immune responses. Commensals such as <em>Staphylococcus epidermidis</em> promote homeostasis by regulating barrier integrity, T-cell activation, and wound repair, while dysbiosis exacerbates immune dysregulation. Innovative strategies, including the use of genetically modified microorganisms to stimulate antigen-specific immunity, hold promise for next-generation therapies. This review underscores the significance of antigen-specific immunity in skin diseases and the emerging role of microbiota in modulating immune responses. Future research into these areas is pivotal for advancing targeted therapies and understanding the interconnectedness of skin health and systemic immunity.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 557-567"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mast cells activated in vitro can modulate macrophage polarization and antibacterial responses","authors":"Dorothea B. Holter MD ,&nbsp;Sophie Zahalka PhD ,&nbsp;Jessica Brösamlen MSc ,&nbsp;Mariem Radhouani DVM ,&nbsp;Martin L. Watzenboeck MD, PhD ,&nbsp;Tyler J. Artner MSc ,&nbsp;Asma Farhat MSc ,&nbsp;Riem Gawish PhD ,&nbsp;Karin Lakovits ,&nbsp;Anastasiya Hladik ,&nbsp;Federica Quattrone PhD ,&nbsp;Wolfgang Weninger MD ,&nbsp;Thomas Krausgruber PhD ,&nbsp;Shane J.F. Cronin PhD ,&nbsp;Shweta Tikoo PhD ,&nbsp;Rohit Jain PhD ,&nbsp;Sylvia Knapp MD, PhD ,&nbsp;Nikolaus Fortelny PhD ,&nbsp;Philipp Starkl PhD","doi":"10.1016/j.jaci.2025.02.040","DOIUrl":"10.1016/j.jaci.2025.02.040","url":null,"abstract":"<div><h3>Background</h3><div>Mast cells and macrophages are tissue-resident immune cells frequently found in close proximity in barrier organs. Macrophages show high plasticity and microenvironmental factors, such as cytokines, can influence their phenotype. Mast cells are central in allergic reactions where allergens cause mast cell activation via antigen-specific IgE antibodies and the release of a multitude of inflammatory substances. While macrophages have clearly defined physiologic roles in tissue maintenance and host defense against microbes, biological mast cell functions are less well defined.</div></div><div><h3>Objective</h3><div>In the current study, we aimed to understand the interplay of mast cells and macrophages and how mast cell–released mediators can shape macrophage phenotype and function.</div></div><div><h3>Methods</h3><div>Using primary <em>in vitro</em> models of mast cells and macrophages combined with microscopic, functional, metabolic, genetic, and epigenetic analyses, we investigate the macrophage polarization effects of mast cell mediators produced on activation with IgE and antigen. We apply a macrophage engraftment strategy to explore potential <em>in vivo</em> implications of mast cell–mediated priming.</div></div><div><h3>Results</h3><div>We find that preformed and newly synthesized mediators released by activated mast cells shape a macrophage phenotype different from the classical M1/M2 macrophage paradigm. Exposure to supernatant of activated mast cells induces epigenetic reprogramming of macrophages. This profound priming effect strongly alters macrophage phagocytosis, cytokine production, and transcriptomic responses on secondary exposure to bacteria or their products. Importantly, <em>in vivo</em> transfer of primed macrophages also significantly affects the outcome of sterile inflammation and bacterial peritonitis.</div></div><div><h3>Conclusion</h3><div>Our study highlights the great potential of activated mast cells as directors of macrophage function.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 754-773"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized therapeutic approaches for asthma","authors":"Ioana Agache MD ,&nbsp;Ian M. Adcock PhD ,&nbsp;Federico Baraldi MD ,&nbsp;Kian Fan Chung MD, DSc ,&nbsp;Ibon Eguiluz-Gracia MD, PhD ,&nbsp;Sebastian L. Johnston MD, PhD ,&nbsp;Marek Jutel MD ,&nbsp;Parameswaran Nair MD, PhD ,&nbsp;Alberto Papi MD ,&nbsp;Celeste Porsbjerg MD, PhD ,&nbsp;Omar S. Usmani MD, PhD ,&nbsp;Deborah A. Meyers PhD ,&nbsp;Magdalena Zemelka-Wiacek PhD ,&nbsp;Eugene R. Bleecker MD","doi":"10.1016/j.jaci.2025.03.025","DOIUrl":"10.1016/j.jaci.2025.03.025","url":null,"abstract":"<div><div>Differences in host susceptibility and environmental exposures result in significant heterogeneity in asthma clinical expression, natural evolution, and response to treatment. These differences are influenced by many factors including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, many of which are modified by environmental and allergic exposures. The complex and multiple characteristics that interact in asthma development and progression pose significant challenges for personalized management. This review aims to guide the clinician in its management decisions by reviewing each of the components important in developing this therapeutic paradigm and by providing several integrated goals for precision or personalized medicine for asthma. Biologic characteristics of asthma in relation to the genomics, exposome, and hypersensitivity reactions (allergic responsiveness) resulting in asthma diathesis are discussed. Further insights including the use of targeted biologics and allergen immunotherapy are provided, while discussing the importance of targeting the epithelium, mucus production, airway smooth muscle, and small airways. We examine the value of multivariate cluster analyses as a new paradigm that can inform treatment decisions and the potential of adaptive trial design to evaluate known and novel predictive biomarkers and characterize disease heterogeneity.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 503-522"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabinoid WIN55,212-2 restores bronchial epithelium by regulating oxidative stress and STAT6 phosphorylation","authors":"Mario Pérez-Diego PhD ,&nbsp;Alba Angelina PhD ,&nbsp;Yağız Pat MD ,&nbsp;Angel Maldonado MSc ,&nbsp;Carmen Sevilla-Ortega PhD ,&nbsp;Leticia Martín-Cruz PhD ,&nbsp;Duygu Yazici PhD ,&nbsp;Beate Rückert MSc ,&nbsp;Milena Sokolowska MD, PhD ,&nbsp;Mar Martín-Fontecha PhD ,&nbsp;Mübeccel Akdis MD, PhD ,&nbsp;Cezmi A. Akdis MD ,&nbsp;Oscar Palomares PhD","doi":"10.1016/j.jaci.2025.05.002","DOIUrl":"10.1016/j.jaci.2025.05.002","url":null,"abstract":"<div><h3>Background</h3><div>Viral infections and type 2 immune responses perpetuate airway epithelial barrier dysfunction and inflammation, leading to the development and progression of asthma. The synthetic cannabinoid WIN55,212-2 displays anti-inflammatory properties by acting on different immune system cells.</div></div><div><h3>Objective</h3><div>We sought to investigate the capacity of WIN55,212-2 to restore bronchial epithelial barrier function in asthma in the context of viral infections or type 2–driven inflammation.</div></div><div><h3>Methods</h3><div>Air-liquid interface cultures of human bronchial epithelial cells and human bronchial epithelial spheroids were generated to assess the capacity of WIN55,212-2 to restore airway epithelial barrier damage induced by human rhinovirus A16 (RV-A16) infection or type 2 inflammation. RT-PCR, cytokine quantification, permeability assays, metabolic studies, flow cytometry, and Western blot techniques were employed to assess the effects of WIN55,212-2 on the airway epithelium. The <em>in vivo</em> relevance of our findings was evaluated in a murine model of IL-13-induced airway inflammation.</div></div><div><h3>Results</h3><div>Prophylactic and therapeutic administration of WIN55,212-2 accelerated the recovery from RV-A16-induced bronchial epithelial barrier damage. WIN55,212-2 inhibited the acquisition of IL-13-induced type 2 asthma features in air-liquid interface cultures, self-assembled bronchial epithelial spheroids, and <em>in vivo</em> asthma model of airway inflammation and epithelial dysfunction. Mechanistically, WIN55,212-2 impaired IL-13-induced oxidative stress in epithelial cells, restoring the activity of protein tyrosine phosphatases, which in turn inhibited pSTAT6-mediated signaling pathways and asthma features.</div></div><div><h3>Conclusions</h3><div>The cannabinoid WIN55,212-2 displays airway epithelial barrier protective effects during RV-A16 infection or type 2 inflammation by mechanisms associated with the modulation of oxidative metabolism and pSTAT6-mediated signaling.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 651-667"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144087530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Where are they now?” Catching up with the 2020 AAAAI Faculty Development Awardees","authors":"Zuhair K. Ballas MD","doi":"10.1016/j.jaci.2025.07.005","DOIUrl":"10.1016/j.jaci.2025.07.005","url":null,"abstract":"","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 604-606"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Child Opportunity Index at birth and asthma with recurrent exacerbations in the US ECHO program","authors":"Rachel L. Miller MD ,&nbsp;Holly Schuh PhD, MPH ,&nbsp;Aruna Chandran MD, MPH ,&nbsp;Rima Habre ScD ,&nbsp;Jyoti Angal PhD, MPH ,&nbsp;Izzuddin M. Aris PhD ,&nbsp;Judy L. Aschner MD ,&nbsp;Casper G. Bendixsen PhD ,&nbsp;Jeffrey Blossom MA ,&nbsp;Michelle Bosquet-Enlow PhD ,&nbsp;Carrie V. Breton ScD ,&nbsp;Carlos A. Camargo Jr. MD, DrPH ,&nbsp;Kecia N. Carroll MD, MPH ,&nbsp;Sarah Commodore PhD ,&nbsp;Lisa A. Croen PhD ,&nbsp;Dana M. Dabelea MD, PhD ,&nbsp;Sean C.L. Deoni PhD ,&nbsp;Assiamira Ferrara MD, PhD ,&nbsp;Rebecca C. Fry PhD ,&nbsp;Jody M. Ganiban PhD ,&nbsp;Lynne M. Smith","doi":"10.1016/j.jaci.2025.02.036","DOIUrl":"10.1016/j.jaci.2025.02.036","url":null,"abstract":"<div><h3>Background</h3><div>Environmental exposures and social determinants likely influence specific childhood asthma phenotypes.</div></div><div><h3>Objective</h3><div>We hypothesized that the Child Opportunity Index (COI) at birth, measuring multiple neighborhood opportunities, influences incidence rates (IRs) for asthma with recurrent exacerbations (ARE).</div></div><div><h3>Methods</h3><div>We tested for COI associations with ARE IRs in 15,877 children born between 1990 and 2018 in the ECHO (Environmental Influences on Child Health Outcomes) program. Parent-reported race and ethnicity and other demographics were assessed as effect modifiers.</div></div><div><h3>Results</h3><div>The IRs of ARE for children born in very low COI neighborhoods was higher (IR = 10.98; 95% CI: 9.71, 12.25) than for other COI categories. Rates for non-Hispanic Black (NHB) children were significantly higher than non-Hispanic White children in every COI category. The ARE IRs for children born in very low COI neighborhoods were several-fold higher for NHB and Hispanic Black children (IR = 15.30; 95% CI: 13.10, 17.49; and IR = 18.48; 95% CI: 8.80, 28.15, respectively) when compared to White children. Adjusting for individual-level characteristics, children born in very low COI neighborhoods demonstrated an ARE IR ratio of 1.26 (95% CI: 0.99, 1.59) with a higher incidence of cases among children ages 2 to 4 years and with a parental history of asthma.</div></div><div><h3>Conclusions</h3><div>Rates of ARE were higher among children born in under-resourced communities, and this relationship is strongest for young minoritized children with a parental history of asthma. Higher rates for NHB even in the highest COI categories suggest that risk associated with race persists regardless of social disadvantage.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 627-639"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of allogeneic hematopoietic stem cell transplantation on pulmonary complications in adults with inborn errors of immunity","authors":"Aurélie Le Gal MD ,&nbsp;Ambroise Marçais MD, PhD ,&nbsp;Céline Goyard MD ,&nbsp;Anne-Laure Brun MD ,&nbsp;Morgane Cheminant MD, PhD ,&nbsp;Nizar Mahlaoui MD, PhD ,&nbsp;Claire Givel MD ,&nbsp;Colas Tcherakian MD, PhD ,&nbsp;Alexandre Chabrol MD ,&nbsp;Frédéric Wallyn MD ,&nbsp;Leonardo Magro MD ,&nbsp;Flore Sicre de Fontbrune MD ,&nbsp;Regis Peffault de la Tour MD, PhD ,&nbsp;Abdellatif Tazi MD, PhD ,&nbsp;Amira Benattia MD ,&nbsp;Remi Valter MD ,&nbsp;Philippe Devillier MD, PhD ,&nbsp;Louis-Jean Couderc MD, PhD ,&nbsp;Felipe Suarez MD, PhD ,&nbsp;Emilie Catherinot MD, PhD ,&nbsp;Hélène Salvator MD, PhD","doi":"10.1016/j.jaci.2025.04.032","DOIUrl":"10.1016/j.jaci.2025.04.032","url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary involvement (repeated lung infections, lung parenchymal inflammation, scarring, and malignancies) is frequent in patients with inborn errors of immunity (IEIs) and accounts for a significant proportion of the disease burden. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure most severe IEIs. The indications for allo-HSCT have recently been extended to adults.</div></div><div><h3>Objective</h3><div>We sought to assess the impact of allo-HSCT specifically on respiratory status.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data of 50 patients with IEIs who underwent a first allo-HSCT after the age of 16 at 3 expert centers in France.</div></div><div><h3>Results</h3><div>The median length of follow-up was 4.8 years (interquartile range: 1.6-9.2) before allo-HSCT and 3 years (interquartile range: 1.4-6.0) after allo-HSCT. Ten patients died as a result of allo-HSCT–related complications. Four patients developed bronchiolitis obliterans syndrome. After 1-year posttransplantation, the mean annualized rate of severe respiratory infections (0.14 [95% CI: 0.04 to 0.24]) was lower than the value recorded before transplantation (0.54 [95% CI: 0.25 to 0.82]; <em>P</em> = .003 for paired comparisons of equivalent durations). Lung function was declining before allo-HSCT (mean FEV₁: −2.09% predicted/year [95% CI: −7.27 to 3.09]) but increased afterward (+2.44% predicted/year [95% CI: −4.79 to 9.69], <em>P</em> = .0034 for paired comparisons). On computed tomography scans of the chest, bronchial disorders and lung parenchyma cavities were the most frequent abnormal findings. The bronchial thickening and bronchiolar micronodules regressed after allo-HSCT, whereas bronchiectasis and residual parenchymal cavities were stable.</div></div><div><h3>Conclusions</h3><div>allo-HSCT seems likely to protect the long-term pulmonary prognosis of adults with IEIs; it is associated with a significantly lower incidence of severe respiratory infections, better lung function, and radiologic stabilization of lung damage.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 825-834"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144083366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neighborhoods—opportunity or harm?","authors":"Markus J. Ege MD, MPH","doi":"10.1016/j.jaci.2025.06.026","DOIUrl":"10.1016/j.jaci.2025.06.026","url":null,"abstract":"","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 607-608"},"PeriodicalIF":11.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}